UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

13 UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups

Jun

06 UCB Hosts HRH Princess Astrid and Belgian Economic Mission at Atlanta Campus

Today, UCB was pleased to host Her Royal Highness Princess Astrid of Belgium (HRH), Belgian dignitaries, and Belgian business leaders to visit our U.S. headquarters in Atlanta, Georgia.

Jun

01 Life with MG & What I Wish For Everyone Who is Diagnosed

May

27 My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

May

23 UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

May

23 First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

May

12 Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

May

10 Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively.

Categories

Archives

Jun

13

UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups

Jun

06

UCB Hosts HRH Princess Astrid and Belgian Economic Mission at Atlanta Campus

Jun

01

Life with MG & What I Wish For Everyone Who is Diagnosed

May

27

My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

May

23

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

May

23

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

May

12

Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

May

10

Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Choose a Country

UCB in the U.S.

Patients

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Jun

13

UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups

Jun

06

UCB Hosts HRH Princess Astrid and Belgian Economic Mission at Atlanta Campus

Jun

01

Life with MG & What I Wish For Everyone Who is Diagnosed

May

27

My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

May

23

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

May

23

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

May

12

Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

May

10

Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Choose a Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Disease Areas

Sustainability

Newsroom

Contact